Evaluation of CCR5-Î"32 mutation and HIV-1 surveillance drug-resistance mutations in peripheral blood mononuclear cells of long-term non progressors of HIV-1-infected individuals
Future Virology
; 17(7):429-439, 2022.
Artigo
em Inglês
| EMBASE | ID: covidwho-2032730
ABSTRACT
Aim:
This study aimed to evaluate chemokine receptor 5 delta 32 (CCR5-δ32) mutation and HIV-1 surveillance drug-resistance mutations (SDRMs) in peripheral blood mononuclear cells of long-term non progressors (LTNPs) of HIV-1-infected individuals. Materials &methods:
This research was performed on 197 treatment-naive HIV-1-infected patients. After follow-up, it was determined that 15 (7.6%) of these people were LTNPs. The PCR assay was performed to identify the CCR5 genotype and HIV-1 SDRMs.Results:
One (6.7%) of the LTNPs was heterozygous (wt/δ32) for the CCR5 delta 32 (CCR5δ32). However, none of the individuals was homozygous for this mutation (δ32/δ32). Moreover, none of the LTNPs showed HIV-1 SDRMs. The CRF35-AD subtype was the most dominant subtype, with a percentage of 93.3%.Conclusion:
Iranian elite controllers are negative for CCR5-delta 32 homozygous genotype and drug resistance against antiretroviral drugs.
LightMix; nucleic acid isolation kit; polymerase chain reaction system; SARS coronavirus test kit; SuperScript III Platinum One-Step; virus RNA; article; clinical article; controlled study; e gene; evaluation study; human; nonhuman; np gene; orf1ab gene; real time polymerase chain reaction; sensitivity analysis; Severe acute respiratory syndrome coronavirus 2; virus detection; virus gene; StepOnePlus
Texto completo:
Disponível
Coleções:
Bases de dados de organismos internacionais
Base de dados:
EMBASE
Tipo de estudo:
Estudo experimental
Idioma:
Inglês
Revista:
Future Virology
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS